Concerns about an economic slowdown have not prevented Axa Framlington Health, a specialist investment management firm, from engaging in deals with health care businesses, particularly in biotechnology, medical devices and pharmaceuticals. Its takeovers in 2007 -- including Medtronic's acquisition of medical device maker Kyphon and AstraZeneca's purchase of MedImmune -- have benefited the company, which describes itself as a "very bottom-up focused" fund.

Related Summaries